Eurofins Discovery enhances drug discovery programs with a comprehensive selection of Helicase assays and panels, including unwinding and ATPase activities, that are compatible with high-throughput screening. Our experts provide in-depth evaluation of helicase activity to support your oncological, infections disease and CNS drug discovery programs.
Helicases are key targets in different areas of therapeutic research, and have a critical role in cellular processes such as DNA replication, transcription, recombination, ribosome biogenesis, and repair. Overexpressed in various types of cancer, these enzymes offer a promising target for the development of specific inhibitors. Focusing on helicases can enrich the precision treatment arsenal, reduce adverse effects, and potentially lead to first-in-class therapies.
Eurofins Discovery can provide helicase solutions to support you at every stage of your drug discovery program:
Advanced Helicase Unwinding Assays
Eurofins Discovery’s unwinding helicase activity assays are specifically designed to evaluate molecules in a robust, repeatable format compatible with HTS. Additionally, we provide custom development options utilizing a dedicated substrate library to create and optimize a highly specific assay for your helicase of interest.
Unwinding Activity
Helicase ATPase Assays
Our ATPase helicase activity assay is a fast and reliable test that screens molecules for their ability to inhibit all functions of the enzyme. At Eurofins Discovery, we have designed this assay to not only identify potent inhibitors but also to ensure their selectivity against other helicases.
ATPase Activity
We currently offer an ATPase Helicase Panel that evaluates a molecule’s specificity against 16 DNA or RNA helicases in an off-the-shelf format.
Profile of specific inhibitors targeting helicase included in the panel:
Tailored Helicase Solutions
Our R&D Teams have access to both full-length and truncated helicase proteins, compatible with biochemical or biophysical analyses. Our experts design tailored screening cascades to fully characterize the selectivity, mode of action and binding modalities of your inhibitors using proteins developed by Eurofins DiscoverX®. Furthermore, it is possible to use the same protein for both hit finding and for mode of action characterization, ensuring a continuity in your program.
Available proteins and assays:
